Fiscal Period | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|
Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
Cash | 12.76 | 11.05 | 22.53 | 1.29 |
Short Term Investments | 135.28 | 103.57 | 24.53 | 3.50 |
Cashand Short Term Investments | 148.04 | 114.63 | 47.06 | 63.73 |
Accounts Receivable- Trade Net | 10.95 | 20.87 | 15.58 | 12.66 |
Total Receivables Net | 10.95 | 24.91 | 15.58 | 12.66 |
Total Inventory | 15.00 | 23.64 | 29.74 | 29.72 |
Other Current Assets Total | 25.26 | 0.32 | 15.64 | 12.51 |
Total Current Assets | 199.25 | 164.56 | 109.08 | 118.63 |
Property/ Plant/ Equipment Total- Net | 9.30 | 24.28 | 22.57 | 23.35 |
Long Term Investments | 5.17 | 3.77 | 29.06 | 21.60 |
Note Receivable- Long Term | 1.25 | 0.31 | 1.07 | 0.57 |
Other Long Term Assets Total | 2.11 | 2.03 | 2.42 | 0.64 |
Total Assets | 217.08 | 194.95 | 164.23 | 164.81 |
Accounts Payable | 7.60 | 16.36 | 18.55 | 20.13 |
Current Portof LT Debt/ Capital Leases | 1.38 | 0.75 | 0.00 | 0.00 |
Other Currentliabilities Total | 10.15 | 10.08 | 7.93 | 10.11 |
Total Current Liabilities | 19.13 | 27.57 | 26.97 | 37.03 |
Capital Lease Obligations | 7.56 | 5.25 | 0.00 | 0.00 |
Total Long Term Debt | 7.56 | 5.25 | 0.00 | 0.00 |
Total Debt | 8.94 | 6.00 | 0.00 | 6.79 |
Deferred Income Tax | 2.07 | 2.16 | 3.24 | 2.00 |
Other Liabilities Total | 0.92 | 1.08 | 1.26 | 0.02 |
Total Liabilities | 29.68 | 36.06 | 31.47 | 39.04 |
Common Stock Total | 13.22 | 13.10 | 13.10 | 13.10 |
Retained Earnings( Accumulated Deficit) | 174.18 | 145.10 | 111.17 | 112.67 |
Total Equity | 187.40 | 158.89 | 132.76 | 125.77 |
Total Liabilities Shareholders' Equity | 217.08 | 194.95 | 164.23 | 164.81 |
Total Common Shares Outstanding | 2.64 | 2.62 | 2.62 | 2.62 |
Tangible Book Valueper Share Common Eq | 70.88 | 60.65 | 50.66 | 48.00 |
Prepaid Expenses | - | 1.07 | 1.06 | - |
Property/ Plant/ Equipment Total- Gross | - | 32.87 | 58.10 | - |
Accumulated Depreciation Total | - | -8.59 | -35.53 | - |
Goodwill Net | - | 0.00 | 0.03 | 0.03 |
Accrued Expenses | - | 0.38 | 0.49 | - |
Notes Payable/ Short Term Debt | - | 0.00 | 0.00 | 6.79 |
Additional Paid- In Capital | - | 0.60 | 0.60 | - |
Unrealized Gain( Loss) | - | 0.00 | 0.00 | - |
Other Equity Total | - | 0.09 | 7.89 | - |
Cash Equivalents | - | - | - | 58.94 |
Jagsonpal Pharmaceuticals Dividend Jagsonpal Pharmaceuticals Bonus Jagsonpal Pharmaceuticals News Jagsonpal Pharmaceuticals AGM Jagsonpal Pharmaceuticals Rights Jagsonpal Pharmaceuticals Splits Jagsonpal Pharmaceuticals Board Meetings Jagsonpal Pharmaceuticals Key Metrics Jagsonpal Pharmaceuticals Shareholdings Jagsonpal Pharmaceuticals Profit Loss Jagsonpal Pharmaceuticals Cashflow Jagsonpal Pharmaceuticals Q1 Results Jagsonpal Pharmaceuticals Q2 Results Jagsonpal Pharmaceuticals Q3 Results Jagsonpal Pharmaceuticals Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks